Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 10/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23768871 | 0.86 | CA5A (0.35) | KLKB1DPP4CA5A | |
| SCHEMBL23769178 | 0.85 | ALDH1A1 (0.51) | BTKKLKB1 | |
| SCHEMBL23769333 | 0.81 | BTK (0.43) | BTKKLKB1 | |
| SCHEMBL23830189 | 0.81 | KLKB1 (0.39) | KLKB1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL18816632 | 0.78 | BTK (0.58) | BTKKLKB1 | |
| SCHEMBL18816573 | 0.78 | BTK (0.56) | BTKKLKB1DPP4 | |
| SCHEMBL18795077 | 0.73 | BTK (0.55) | BTK | |
| SCHEMBL21712947 | 0.73 | KLKB1 (0.59) | BTKKLKB1 | |
| SCHEMBL31033203 | 0.73 | KLKB1 (0.59) | BTKKLKB1 | |
| SCHEMBL21712925 | 0.73 | KLKB1 (0.60) | BTKKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| US-20210292301-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-09-23 | — | — | US | disclosed |
| WO-2021160718-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292301-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | BTK 1516/4885KLKB1 1/4885DPP4 780/4885 |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | BTK 1516/4885KLKB1 1/4885DPP4 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.